Actively Recruiting
Wilson's Disease Treated With D-Penicillamine: Characterization of Skin Damage Secondary to Treatment by Measuring Skin Elasticity
Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2026-01-23
120
Participants Needed
2
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Wilson's disease is a genetic disorder, resulting from an anomaly present on the ATP7B gene located on chromosome 13, causing a progressive accumulation of copper in various organs such as the liver, nervous system and cornea, leading to various hepatic and neurological disorders and a systemic evolution. Currently, the first-line treatment for this disease is D-Penicillamine, which acts by chelation and promotes copper excretion through the urine. Unfortunately, this treatment also has significant side-effects, particularly on the skin. However, the pathogenesis of elastopathy in patients with Wilson's disease has yet to be fully characterized, and needs to be better understood in order to adapt the therapeutic strategy. A silicon mold will be made on Wilson's disease patients, enabling the skin micro-relief to be shaped, and analyzed by confocal laser in comparison with the skin of healthy volunteers.
CONDITIONS
Official Title
Wilson's Disease Treated With D-Penicillamine: Characterization of Skin Damage Secondary to Treatment by Measuring Skin Elasticity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient over 12 years old
- Patient with Wilson's disease confirmed by genetic analysis
- Patient followed up in the Wilson's Disease Reference Center for care
- Patient treated with D-Penicillamine
- Patient with no other known elastic tissue pathology
- Patient over 12 years old (healthy volunteers)
- Patient followed in the dermatology department of St Etienne University Hospital (healthy volunteers)
- Patient matched on sex and age with a Wilson's disease patient (healthy volunteers)
- Patient with no elastic tissue pathology (healthy volunteers)
- Patient affiliated to a national social security
- Patient with written informed consent
You will not qualify if you...
- Patient taking treatments that may modify skin elasticity
- Patient with pathological lesions on forearm or cheek
- Patient with potentially active or rejuvenative forearm or cheek treatment
- Patient having applied cream or make-up to forearm or cheek before molding
- Patient under guardianship
- Patient unable to follow study procedures
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Hospices Civils de Lyon
Bron, France, 69677
Actively Recruiting
2
Hôpital Nord CHU de Saint-Étienne
Saint-Etienne, France, 42055
Not Yet Recruiting
Research Team
J
Jean Luc PERROT, PHD
CONTACT
E
Eduardo COUCHONNAL-BEDOYA, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here